Home > Research > Publications & Outputs > Cost-effectiveness of levodopa-carbidopa intest...

Associated organisational unit

Electronic data

  • Raj_et_al._2023_AAM_-_RaCES_

    Accepted author manuscript, 317 KB, PDF document

    Available under license: CC BY: Creative Commons Attribution 4.0 International License


Text available via DOI:

View graph of relations

Cost-effectiveness of levodopa-carbidopa intestinal gel in treating people with advanced Parkinson's disease

Research output: Contribution to Journal/MagazineJournal articlepeer-review

  • Sonia Raj
  • Rekha Sarvankar
  • Luís Filipe
  • Valerio Benedetto
  • Nicola Mason
  • Jennifer Dawber
  • James Hill
  • Andrew Clegg
<mark>Journal publication date</mark>2/08/2023
<mark>Journal</mark>British Journal of Neuroscience Nursing
Issue number4
Number of pages5
Pages (from-to)140-144
Publication StatusPublished
<mark>Original language</mark>English


Advanced Parkinson's disease causes further deterioration in the physical and cognitive functions of patients with existing Parkinson's disease. This commentary critically assesses an economic evaluation which compared the cost-effectiveness of levodopa/carbidopa intestinal gel against standard of care in treating patients with advanced Parkinson's disease. While the economic evaluation indicated that levodopa/carbidopa intestinal gel could be cost-effective within the UK parameters, the authors of this commentary highlight important limitations related to its design, modelling and analysis. Future research should consider the incorporation of a separate arm dedicated to the re-infusion of apomorphine in eligible patients with advanced Parkinson's disease, a wider set of levodopa/carbidopa intestinal gel adverse events and related costs, and a sub-group analysis on different socioeconomic strata.